Evidence map›Paper›PMID 26052399›Full record

ReviewWorld journal of hepatology2015

Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin.

Javier Ampuero, Manuel Romero-Gomez

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Diabetes and liver cancer risk: A stronger effect in Whites than Blacks?Journal of diabetes and its complications · 2021
    Article
  9. Article
  10. The Epidemiology of Hepatocellular Carcinoma in the USA.Current gastroenterology reports · 2019
    Review
  11. Review
  12. Review
  13. Article
  14. [Genes and molecular mechanisms affecting the correlation between liver cancer and diabetes mellitus].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018
    Article
  15. Article
  16. Article
  17. Article
  18. Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives.Journal of clinical and translational hepatology · 2017
    Review
  19. Article
  20. Targeting Inflammation in Cancer Prevention and Therapy.Cancer prevention research (Philadelphia, Pa.) · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Javier AmpueroJavier Ampuero, Manuel Romero-Gomez, Unit for the Clinical Management of Digestive Diseases, Valme University Hospital, 41014 Sevilla, Spain.
Manuel Romero-GomezJavier Ampuero, Manuel Romero-Gomez, Unit for the Clinical Management of Digestive Diseases, Valme University Hospital, 41014 Sevilla, Spain.
Hospital Universitario de Valme · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma is the third leading cause of cancer-related deaths in the world. It is associated with an important mortality rate and the incidence is increasing. Patients showing metabolic syndrome seem to have higher incidence and mortality rates from hepatocellular carcinoma than healthy subjects, especially those with type 2 diabetes mellitus and obesity. Thus, metformin and statins, both to treat features of metabolic syndrome, have been proposed to decrease the risk of hepatocellular carcinoma. Otherwise, liver cancer is the result of a complex process which impairs several signaling cascades, such as RAS/RAF/mitogen-activated protein kinase kinase (MEK)/extracellular-signal-regulated kinase (ERK), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) and Wnt/β-catenin signaling. Metformin (through 5'-adenosine monophosphate-activated protein kinase pathway activation) and statins (through 3-hydroxy-3-methylglutaryl coenzyme A inhibition) show anti-tumoral properties modifying several steps of RAS/RAF/MEK/ERK, PI3K/AKT/mTOR and Wnt/β-catenin signaling cascades. On the other hand, metformin and statins have been found to reduce the risk of hepatocellular carcinoma up to 50% and 60%, respectively. Furthermore, both drugs have shown a dose-dependent protective effect. However, information about chemopreventive role of metformin and statins is mainly obtained of observational studies, which could not take into account some bias. In conclusion, given the rising of incidence of hepatocellular carcinoma and the important morbidity and mortality rates associated with this cancer, looking for chemopreventive strategies is an essential task. Randomized controlled trials are needed to determine the definite role of metformin and statins on the prevention of hepatocellular carcinoma.

Indexed as

Hepatocellular carcinomaMammalian target of rapamycinMetabolic syndromeMetforminStatin

Identifiers

PMID26052399
PMCPMC4450187
OpenAlexW607026603

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.